Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.
about
Nanogels as potential nanomedicine carrier for treatment of cancer: A mini review of the state of the artFrom selection hits to clinical leads: progress in aptamer discoveryMicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic ConsiderationssiRNA Delivery by Stimuli-Sensitive NanocarriersUnexpected origins of the enhanced pairing affinity of 2'-fluoro-modified RNAKnocking down disease: a progress report on siRNA therapeuticsNanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicineSilencing disease genes in the laboratory and the clinicMolecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.Chemical modification: the key to clinical application of RNA interference?Applications of mass spectrometry to the study of siRNA.Advances in Systemic siRNA DeliveryComparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9.Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencingEffect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters.Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition.Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells.Efficient and targeted delivery of siRNA in vivo.Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.RNA interference for improving the outcome of islet transplantation.RNAi induces innate immunity through multiple cellular signaling pathways.siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipidsPharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery.Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated deliveryAdministration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.Hydrophobization and bioconjugation for enhanced siRNA delivery and targetingIn vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy.Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.The therapeutic potential of RNA interference.The silent treatment: siRNAs as small molecule drugs.Silencing neurodegenerative disease: bringing RNA interference to the clinic.RNAi for treating hepatitis B viral infection.Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs.Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic FibrosisImmunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model.Interfering with disease: a progress report on siRNA-based therapeutics.Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.Rational design of novel N-alkyl-N capped biostable RNA nanostructures for efficient long-term inhibition of gene expression
P2860
Q26751229-1ED94BAA-F277-465D-B331-541C57DEFC06Q26752799-BC21EE82-3981-441F-BD4E-535B85AD75E7Q26773183-6FA2BF6A-471C-44E9-925C-1F72D8267678Q26781212-732DCB5E-0585-4AB8-ABA7-E63096B064A4Q27666384-D56143DF-643E-4D0A-B711-4E4CAE4C7B46Q28082939-1C742763-C97C-4479-8F9E-514AF72F5055Q28390007-83EAC4C2-01E7-4055-93D3-6FCAC637B321Q29039090-72D2531B-0F9C-4B58-82B7-5B954F288C68Q30502702-DB4FA0F6-C22B-4665-989E-60845D52BDFDQ33308712-DFE5F62B-71D5-4CE2-AEB1-7BFAD549AD88Q33536680-8630B5C7-0138-40D7-A251-02DB6C9BE04DQ33613316-0814B905-4293-4EAB-B075-A73B082FD9FEQ33713259-C65EFDC7-FB41-428D-8DDC-CC2BF301A893Q34020246-B9F09941-3776-448A-A6BB-BD1E9261D7DFQ34080079-B1D99063-41AE-41C2-BAEA-FAD0E16E0212Q34102905-27A8D4F6-F979-4C0C-9D31-9AEAE28A0B9FQ34123971-93079C7A-1616-4BF4-9710-EBD2247EC649Q34149828-1FC915D9-FFF6-491F-8F4D-1EFC8605A9A2Q34436572-2D7FADED-DB7E-4728-A55F-C4C8E221A309Q34729434-8BD69724-28F3-4222-8ABB-A86618042605Q34735628-B81BE08B-6EE6-4C7E-8B1D-A98AD6911D37Q34955791-9D025AEF-1B2B-4AEE-BFF5-461032B03A7BQ35086107-4C9176EF-9724-4A9A-9D25-26F0D2257B49Q35179033-D797A65C-B52B-442F-B920-58A53CC20120Q35681765-87F81703-959E-446A-8547-67BB2AA30942Q35691719-4619F99B-B5E5-46D3-BA4E-F00F8AD7E662Q35697443-5F2C86EE-6023-4B88-9459-9EAC1F7D3722Q35806350-5D54DC1C-D4C3-4D44-8E0A-CE32C7AF2A99Q35928850-F13E3718-EAC3-40F0-8C84-D690A22AC032Q36174842-0BBD2F50-B805-4041-9C63-0DF5FF5CBB4BQ36237868-C0D216D6-716F-407B-A154-87AC57AAF9B0Q36362370-000C655F-CD3B-4FC5-8B41-BBD0750B31C6Q36390831-27938BD5-9263-4A49-A9AC-82CEFB26E152Q36412870-42F97706-C4CC-4DE9-B9AF-BD6B7097CB37Q36452421-E4EF053F-D76F-47B6-BEFB-CE13989DFFE7Q36587576-48E89C0B-E458-41A9-9ABF-837356FA1223Q36821357-6AE93773-C8B0-4883-A4D6-E167B0ED146FQ36836598-79543B5D-DAFF-4D28-9EC5-733B6C81DD04Q36838803-B5167200-52DD-4C9B-93C2-962767FCC56EQ36914607-ABA5261E-5D66-451E-A705-68F95F7DFA09
P2860
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Activity of stabilized short i ...... hepatitis B virus replication.
@ast
Activity of stabilized short i ...... hepatitis B virus replication.
@en
Activity of stabilized short i ...... hepatitis B virus replication.
@nl
type
label
Activity of stabilized short i ...... hepatitis B virus replication.
@ast
Activity of stabilized short i ...... hepatitis B virus replication.
@en
Activity of stabilized short i ...... hepatitis B virus replication.
@nl
prefLabel
Activity of stabilized short i ...... hepatitis B virus replication.
@ast
Activity of stabilized short i ...... hepatitis B virus replication.
@en
Activity of stabilized short i ...... hepatitis B virus replication.
@nl
P2093
P356
P1433
P1476
Activity of stabilized short i ...... hepatitis B virus replication.
@en
P2093
Barry A Polisky
Brent Dickinson
Chandra Vargeese
Chris S Shaffer
David V Morrissey
James A McSwiggen
Jennifer A Lockridge
Karin Blanchard
Keith Bowman
Kristi Jensen
P304
P356
10.1002/HEP.20702
P407
P577
2005-06-01T00:00:00Z